心脏缺血-再输液损伤:病理生理学,治疗目标和未来的干预措施
Lujain Alsadder1, Abdulaziz Hamadah1
1Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 4NS, UK.
Biomedicines
|September 27, 2025
概括
尽管医学的进步,心脏缺血-再输液 (I/R) 损伤仍然是一个重大挑战. 本综述探讨了I / R损伤机制和新兴疗法,以减轻这种并发症.
科学领域:
- 心脏病学 心脏病学
- 生物医学科学 生物医学科学
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,尽管有诊断和管理方面的改进.
- 心脏缺血-再输 (I/R) 损伤是心血管疾病治疗期间的主要并发症,导致矛盾的组织损伤.
- 目前针对心脏I/R损伤的治疗策略不足,需要进一步研究.
研究的目的:
- 审查心脏缺血-再输血 (I/R) 损伤的复杂病理生理学.
- 为了识别了解I/R损伤的知识差距.
- 探索新的和新兴的治疗干预措施,以减轻I/R损伤.
主要方法:
- 对心脏I/R损伤现有研究的文献综述.
- 对潜在机制和促成因素的分析.
- 评估当前和潜在的治疗策略.
主要成果:
- 心脏I/R损伤涉及多方面的病理生理过程,具有复杂的临床结果.
- 现有的I/R损伤治疗方法有局限性,还没有找到最佳解决方案.
- 药理和分子疗法看起来有前途,但需要进一步研究.
结论:
- 了解心脏I/R损伤的复杂机制对于开发有效的治疗方法至关重要.
- 新兴的治疗干预措施有可能减轻I/R损伤.
- 持续的研究对于应对心脏I/R损伤在心血管疾病管理中所带来的挑战至关重要.
相关概念视频
Acute Coronary Syndrome IV: Interprofessional Care
220
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220
Cardiopulmonary Resuscitation IV: Pharmacological Management
665
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
665
Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Ischemic Heart Disease: Overview
3.0K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.0K


